title: Immunotherapy in leukaemia.
abstract: Therapeutic cancer vaccination, e.g. by using tumour antigen-presenting dendritic cells (DCs) that 'educate' the immune system to recognise and attack tumour cells, represents a new concept of treatment in oncology. DCbased immunotherapy elicits both innate (NK) and adaptive (T cells) cellular responses correlated with clinical benefit. WT1 mRNA-transfected DCs emerge as a feasible and effective strategy to control residual disease in acute myeloid leukaemia (AML), in particular as a post-remission treatment to prevent full relapse. This innovative approach takes advantage of the intrinsic potential of the immune system to eradicate malignant disease.
authors: Antwerp University Hospital, Division of Haematology, Edgem, Belgium. Ann.Van.De.Velde@uza.ba
authors: A L R
authors: AL
authors: Van De Velde
authors: S
authors: S
authors: Anguille
authors: Z N
authors: ZN
authors: Berneman
mesh_terms: D000938:Antigen-Presenting Cells / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology*; D019317:Evidence-Based Medicine; D005544:Forecasting; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007694:Killer Cells, Natural / Q000276:immunology; D007938:Leukemia / Q000276:immunology* / Q000628:therapy*; D012307:Risk Factors; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D019496:Cancer Vaccines